Race, response to chemotherapy, and outcome within clinical XXXX subtypes.

@entity1 @entity0 @entity28 @entity5 @entity1349 @entity3004 @entity5282 @entity1722
The effect of race on @entity0 outcome is confounded by @entity5 and treatment heterogeneity. We examined a cohort of @entity1 with @entity0 treated uniformly with neoadjuvant chemotherapy to identify factors associated with racial differences in chemotherapeutic response and long-term survival. Using a prospective database, we identified @entity1 with @entity0 treated with neoadjuvant chemotherapy from 1998 to 2011. Race was categorized @entity3004 ( @entity3004 ) or non- @entity3004 . Preplanned subtype analyses were stratified by @entity5282 ( @entity5282 ) and @entity1722 . Pathologic response to chemotherapy (pCR), time to recurrence (TTR), and @entity1349 ( @entity1349 ) were assessed using logistic regression, Kaplan-Meier method, and Cox proportional hazards regression analyses. Of 349 @entity1 identified, 102 (29 %) were @entity3004 , who were younger (p = 0.03), more @entity28 (p < 0.001), and less likely to have @entity5282 +/ @entity1722 - @entity5 (p = 0.01). No significant differences in pCR rate by race were found. At median follow-up of 6.5 years, @entity3004 had worse TTR (hazard ratio 1.51, 95 % CI 1.02-2.24), which was attenuated in multivariable modeling, and there was no significant difference in @entity1349 . When stratified by @entity5282 , worse outcomes were limited to @entity5282 + @entity3004 (TTR hazard ratio 1.85, 95 % CI 1.09-3.14; @entity1349 hazard ratio 2.42 95 % CI 1.37-4.28), which remained significant in multivariable analysis including pCR rate and BMI. With long-term follow-up, racial disparity in outcome was limited to @entity5282 + @entity0 , with no apparent contribution of chemotherapy sensitivity. This suggests that disparity root causes may be driven by @entity5282 + factors such as unmeasured molecular differences, endocrine therapy sensitivity, or adherence.
